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Adverse drug reactionAbstract Context: To achieve good cure rate during treatment of MDR-TB, strict adherence to
treatment regimen is a must. As the second line drugs have great potential to cause adverse drug
reactions (ADR), identifying these adverse reactions and treating them early is major factor in
preventing default. Hypothyroidism is one such ADR caused by thioamides (ethionamide,
prothionamide) and paraamino salicylic acid.
Aims: To study the frequency of occurrence of hypothyroidism and its implication in MDR-TB
treatment.
Settings and design: Retrospective analysis of 488 patients enrolled in our institute for MDR-TB
treatment treated with standardised Cat IV treatment, as per RNTCP-PMDT guidelines.
Methods and material: Retrospective analysis of 484 (4 had hypothyroidism before treatment
initiation) patients treated in our institute was done. Thyroid function test was done at baseline
and repeated when indicated by symptoms during clinical follow up. Patients developing hypothy-
roidism (deﬁned as TSH > 10 microIU/ml) during treatment and the reasons for same are
analysed. Its implication in treatment outcome is studied.
Results: Out of the 484 study population, 19 (3.9%) had at least one documented record of
TSH> 10.0 microIU/ml after treatment initiation. Median time from initiation of MDR-TB treat-
ment to development of hypothyroidism was 153 days (range 32–441 days).
Conclusions: Occurrence of hypothyroidism is rare in MDRTB treatment. But symptomatic
hypothyroidism is a major factor inﬂuencing the patient compliance towards the treatment regimen.
As the drugs in regimen are effective in disease treatment, the major hindrance in achieving good
cure-rate is to prevent defaulters. Identifying hypothyroidism early helps to prevent default.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).rculosis.
Table 1 Clinical proﬁle of patients.
Number/Mean (range)









Baseline 4.11 (0.01–8) microIU/ml
At diagnosis 12.86 (10.12–30.67) microIU/ml)
Median time 153 days (32–441 days)
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Multidrug drug resistant tuberculosis (MDR-TB) treatment
has effective drug regimen. The major challenge is compliance.
Studies have shown that one of the important causes for
default of treatment is adverse drug reactions. Drugs used
for MDR-TB treatment have a great potential to cause adverse
effects [1,2]. They range from mild gastrointestinal
disturbances, arthralgia to major psychosis, suicidal tendencies
and severe hypothyroidism [3].
Hypothyroidism is a known side effect of thioamides (TA)–
Ethionamide (ETH), Prothionamide (PTH) and Para
aminosalicylic acid (PAS) [4–7]. Hypothyroidism has vague
and non speciﬁc symptoms which can be easily missed.
Various studies have reported hypothyroidism varying from
3.5% to as high as 69% [3,8,9]. Present study was done to ascer-
tain the rate of occurrence of hypothyroidism in MDR-TB
patients treated with standardised cat-IV regimen under pro-
grammaticmanagement of drug resistant tuberculosis (PMDT).
Materials and methods
Retrospective cohort study was done in SDS Tuberculosis
Research Centre and Rajiv Gandhi Institute of Chest
Diseases, Bangalore.
Inclusion criteria: all patients of sputum culture conﬁrmed
MDR-TB enrolled from August 2011 to March 2014.
Exclusion criteria: patients with diagnosed hypothyroidism
or those with pre treatment TSH> 10 microIU/mL.
All conﬁrmed MDR-TB patients were admitted for
pre-treatment evaluation and treatment initiation. As per the
national guidelines thyroid proﬁle was done prior to initiation.
Patients were started on standardised cat IV regimen which
includes Kanamycin, Levoﬂoxacin, Ethionamide,
Pyrazinamide, Ethambutol, Cycloserine for 6–9 months and
Levoﬂoxacin, Ethionamide, Ethambutol and Cycloserine for
18 months. PAS was used as a substitute drug in case of major
adverse effect or initial resistance to any of second line drugs.
After 10–30 days of initial hospitalisation, patients continued
community based treatment at peripheral centres. As per the
PMDT guidelines, they were regularly followed up clinically.
Thyroid function tests are repeated on clinician suspicion of
hypothyroidism. Thyroid stimulating hormone (TSH) was
measured from blood samples using ultra-sensitive sandwich
chemiluminescent assay. Data were collected by reviewing
patients’ case records, treatment cards, registers and reports
sent online. Hypothyroidism is deﬁned as at least one measure
of TSH> 10.0 microIU/ml after initiation of MDR-TB
treatment. Data thus collected were analysed.
Results
From August 2011 till March 2014, 488 patients enrolled for
MDR-TB treatment in SDSTRC and RGICD, Bangalore.
All patients had thyroid proﬁle before initiation of treatment.
4 of them had TSH level more than 10.0 microIU/ml; hence
they were excluded from the study. Out of the 484 study
population, 19 (3.9%) had at least one documented record of
TSH> 10.0 microIU/ml after treatment initiation. The
clinical proﬁle of those 19 patients is shown in Table 1.Mean TSH level of patients who developed hypothyroidism
was 12.86 microIU/ml. Of the 19 patients who developed
hypothyroidism, 17 received only ethionamide and 2 of them
received both Ethionamide and PAS. Median time from
initiation of MDR-TB treatment to development of hypothy-
roidism was 153 days (range 32–441 days). All patients with
TSH> 10 microIU/ml were initiated on levothyroxine 25–
100 lm daily depending on body weight and TSH levels
irrespective of symptoms. TSH levels were monitored regularly
and levothyroxine dose adjusted accordingly. MDR-TB
treatment drugs were not modiﬁed in any of these patients.
Out of these 19 patients who developed hypothyroidisms 5
were declared cured, 4 died and 10 are still on treatment.
Among 4 who died 1 committed suicide, 2 died of non TB
causes and 1 died after diagnosed as XDR-TB (Table 2).
Discussion
Treatment of MDR-TB is challenging. Long duration of
treatment, multiple drug usage and severe drug reactions are
limitations. Many studies have reported adverse drug
reactions. Frequency of such adverse drug reactions ranged
from 57% to 80% in various studies done in India and other
countries [10,11]. These adverse reactions are varied. Some
are minor and few are major. But these major adverse reac-
tions are hindrance for strict adherence of treatment leading
to unfavourable outcome.
Symptomatic hypothyroidism can be disturbing in day to
day life. After the introduction of cat IV, treatment of
MDRTB is standardised and drugs used is same in all patients.
The frequency of adverse drugs reactions with cat IV, particu-
larly the occurrence of hypothyroidism is not studied carefully.
Few studies done in different countries showed the occurrence
of hypothyroidism varying from as low as 3.5% to as high as
69% [3,8,9].
In our study, rate of hypothyroidism after MDR-TB
treatment was 3.9%. This is in contrary to studies from
Egypt [12] (39.5%), Botswana [8] (16.2%), Russia [13]
(17.2%), Peru [14] (10%) and Lesotho [9] (69%). 3.5%
hypothyroidism was reported in one study evaluating adverse
drug reactions collectively from ﬁve DOTS-Plus centres [3].
Studies with a high rate of hypothyroidism had both thioa-
mides (ETH/PTH) and PAS in the treatment regimen.





Hypothyroidism in MDR-TB treatment – Rare occurrence but a major concern 673Patients in our study received only ETH. PAS was used as a
reserve drug. Out of the 19 patients who developed hypothy-
roidism, only 2 received both ETH and PAS. In 1 patient
kanamycin was replaced with PAS due to nephrotoxicity and
in another patient Levoﬂoxacin was replaced with
Moxiﬂoxacin and PAS, as he showed initial resistance to
Levoﬂoxacin.
Mean age of patients who developed hypothyroidism was
31.7 yrs in our study as opposed to 40 yrs in the study done
in Botswana [8]. However the range was from 14 to 55 yrs.
This showed no preponderance to any speciﬁc age. Male or
female preponderance was not seen in our study similar to
the study done in Lesotho where male sex was not statistically
associated with hypothyroidism [9]. None of our patients had
HIV seropositive status and so were not on ART. Use of
Stavudine has been associated with the development of
subclinical hypothyroidism [15].
Baseline TSH of patients who developed hypothyroidism
ranged from 0.01 to 8 microIU/mL (mean 4.11 microIU/mL)
but elevated to >10micoIU/mL after more than 1 month of
treatment. This implies that hypothyroidism was induced by
MDR-TB treatment rather than a pre existing condition.
Elevated TSH levels varied from 10.12 to 30.67 microIU/mL
(mean 12.86 microIU/mL). Study in Lesotho reported that
77.5% of 129 patients who developed hypothyroidism had
TSH> 20 microIU/mL in contrast to our study where only
2 (10.5%) had TSH > 20 microIU/mL [9].
Few studies monitored TSH regularly during treatment like
every 2 months or at 6 and 12 months [9,13]. These studies
reported high rate (17.2%, 69%) of hypothyroidism. 2 studies
reporting 10% and 16.2% were measuring TSH as and when
indicated [8,14]. In our study TSH was repeated after baseline
test based on clinicians’ decision and not routinely.
Hypothyroidism has non-speciﬁc symptoms (fatigue, cold
intolerance, dry skin, constipation, unexplained weight gain,
menstrual disturbances, depression etc.) which may be easily
missed by the treating clinicians or may be confused with the
side effects of other second line drugs. WHO guidelines
recommend screening for hypothyroidism at 6–9 months after
initiation of MDR-TB treatment [16].
Median time to hypothyroidism was found to be 153 days
(range 32–441 days) in our study. Other studies had median
time between 93 and 300 days [8,9,13,14]. Only 3 (15.7%)
developed hypothyroidism between 2 and 3 months whereas
majority became symptomatic after 3 months of treatment.
The 2 patients who were on both ETH and PAS had elevated
TSH level of 11–12 microIU/mL; 1 after 32 days and the other
after 441 days of treatment. Whether combined ETH and PAS
synergistically leads to hypothyroidism early in the course of
treatment could not be ascertained. Studies which used both
ETH and PAS in the treatment regimen had median time to
hypothyroidism between 93 and 120 days.[9,13]Patients developing hypothyroidism continued the same
treatment regimen with favourable outcome. None of the
patients diagnosed with hypothyroidism defaulted. The fact
that 1 patient committed suicide needs attention. Suicidal
tendencies are known side effect of cycloserine but depression
is also a symptom of hypothyroidism. Delay in identifying the
same could be a reason.
Our study had several limitations. Being a retrospective
study data might have been lost. Patients were non compliant
for regular clinical monitoring. Subtle symptoms of hypothy-
roidism may have been missed by the clinicians as TSH was
not monitored regularly leading to under-diagnosis. Hence a
prospective study is needed to ascertain the real magnitude
of hypothyroidism.Conclusion
Hypothyroidism rate was low in our cohort. The diagnosed
cases may represent only the tip of the ice berg.
Unrecognised hypothyroidism may lead to unfavourable
outcome like death or default in MDR-TB treatment.
Prompt recognition and treatment of hypothyroidism can lead
to adherence of treatment with successful outcome.
Monitoring with TSH levels even in asymptomatic cases at
regular intervals like 3 months and again between 6 and
9 months of MDR-TB treatment may be considered optimal.Conﬂict of interest
None declared.
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